Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that occurs in children and adolescents. Despite significant insights in T-ALL biology, only limited therapeutic options are available for patients with primary resistant or relapsed disease. Current T-ALL treatment schedules consist of high dose chemotherapy and are often associated with acute and chronic life threatening and debilitating toxicities [1] [2] [3] . Consequently, there is an urgent clinical need for optimized treatment stratification and more effective antileukemic drugs for the treatment of human T-ALL 3 .
Genetic studies have collectively shown that T-ALLs can be divided into subgroups that are characterized by unique gene expression signatures and relate to stages of T-cell differentiation at which the leukemic cells arrest. Each molecular subgroup has characteristic genetic abnormalities that cause aberrant activation of specific T-ALL transcription factor oncogenes, including LYL1/MEF2C, HOXA, TLX1, TLX3 and TAL1/LMO2 driven T-ALL [3] [4] [5] [6] . Notably, the recently described Early T-cell Precursor In an effort to improve patient prognosis and survival, targeted therapeutics are beginning to emerge as powerful agents against hematological malignancies. One such example is the small molecule ABT-199, a highly potent, orally bioavailable BCL-2 specific inhibitor 13 . The anti-tumor effects of . Currently, phase-I clinical trials of are ongoing and the first preliminary results show a high overall response rate.
ALL (ETP-ALL) patients
Notably, some patients included in this trial experienced tumor lysis syndrome as a result of the massive cell death induced by .
Given these promising anti-tumor results for ABT-199, we sought to establish the extent and level of BCL-2 expression across different T-ALL molecular subgroups and evaluated the therapeutic potential of the BCL-2 inhibitor in the context of human T-ALL.
Methods

Patient samples, cell lines and mouse tumor cells
The cell lines were purchased from the DSMZ repository (Braunschweig, Germany) and cultured in RPMI 1640 medium supplemented with 10% or 20% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml kanamycin sulfate and 2 mM Lglutamine at 37°C with 5% CO 2 .
Bone marrow lymphoblast samples from 64 T-ALL patients (15 immature, 25
TAL/LMO, 17 TLX1/TLX3 and 7 HOXA) were collected with informed consent according to the declaration of Helsinki from Saint-Louis Hospital (Paris, France) and the study was approved by the Institut Universitaire d'Hematologie Institutional
Review Board. This primary T-ALL cohort was previously investigated 21 and the highquality RNA samples from this cohort were used for gene expression profiling.
Primary T-ALL cells for in vitro ABT-199 treatment and xenograft studies were acquired by informed consent from the Department of Pediatric Hemato-Oncology at Ghent University Hospital. These primary T-ALL samples were assigned to a specific molecular genetic subclass based on RT-PCR of SIL-TAL1 or MLL fusion transcripts, TLX1/TLX3 expression analysis by qPCR or FISH analysis of the LMO2 locus.
Leukemic T-cells obtained from splenic tissue derived from secondary transplanted tumors that originally developed in the Lck-Lmo2 mouse model (KR & THR, manuscript in preparation) were a kind gift of Prof. Terence Rabbitts.
Isolation of thymocyte subsets from human thymus tissue
Human thymocytes were extracted from thymus tissue, from children undergoing cardiac surgery and was obtained and used according to the guidelines of the 
Gene expression profiling of primary T-ALL samples and T-cell subsets
Total RNA was isolated using the miRNeasy or RNeasy mini kit (Qiagen) and the RNA quality was evaluated on the Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Whole human genome expression profiling was performed using the GeneChip Human Genome U133 2.0 Plus arrays (Affymetrix, Santa Clara, CA, USA) according to standardized procedures at the IGBMC (www.igbmc.fr, Strasbourg, France). Normalization of microarray intensities was done using the variance stabilization and calibration (VSN) R package in R. Differential expression analysis was done using the Comparative Marker Selection module in GenePattern
22
.
Microarray data have been deposited in GEO with accession number GSE62156.
Treatment of cells with ABT-199 followed by viability or apoptosis assay
Cells from T-ALL cell lines (Supplementary values were calculated using the Calcusyn software (Biosoft, Cambridge, MA). The experiment was performed two or three times independently and in every experiment itself each concentration was tested in duplicate for every cell line.
For the apoptosis assay, cells were plated at 10 000 cells per well in 96-well plates.
The cells were incubated for 24h in 95µl medium with 10% FBS to which 5µl of the appropriate ABT-199 dilution or DMSO was added. The assay was performed with the Caspase-Glo 3/7 Assay according to the manufacturer's instructions (Promega).
The experiment was performed three times and every concentration point was each time tested in duplicate for each cell line.
For the treatment of primary T-ALLs, enriched mononuclear cells or full bone marrow from primary leukemia samples were suspended in complete culture medium supplemented with 10% FBS. Cells were plated at 50 000 cells per well in 96-well plates to which 5µl of the appropriate ABT-199 dilution (9 to 13 concentrations) or DMSO was added (total volume 100µl). Cell viability was measured 16h after adding the compound and the IC 50 values were calculated. Each concentration was tested in duplicate for every patient sample. The Lck-Lmo2 mouse tumor T-cells were thawed and treated with ABT-199 in medium with 10% FBS for 16h. The IC 50 values were determined as described above (50 000 cells per well). Two independent experiments were performed in which each concentration was tested in duplicate.
Real Time Quantitative Polymerase Chain Reactions (qRT-PCR)
Total RNA was isolated using the miRNeasy mini kit (Qiagen) and the RNAse-Free Dnase set (Qiagen). The iScript cDNA synthesis kit (Bio-Rad) was used to synthesize cDNA. The qRT-PCRs were performed using the SsoAdvanced SYBR Green Supermix (Bio-Rad) and were run on the LightCycler 480 (Roche, model LC480).
Every sample was analyzed in duplicate and the gene expression was standardized against at least 3 housekeeping genes. The primer sequences are listed in Supplementary polyacrylamide gel and the SDS-PAGE was run followed by blotting on a nitrocellulose membrane. The used primary antibodies were: Bcl-2 antibody (C-2) (sc-7382, Santa Cruz Biotechnology, dilution 1:1000), BCL-X L antibody (#2762, Cell Signaling Technology, dilution 1:1000) and anti-β-actin antibody (Clone AC-75, A2228, Sigma-Aldrich, dilution 1:2000). The protein bands were densitometric analyzed using ImageJ.
In vivo treatment of xenografts with ABT-199
Luciferase positive LOUCY cells were generated by infecting the LOUCY cell line with PWPI-LUC lentiviruses. Non-concentrated virus was produced in HEK293TN cells using JetPEI polyplus reagent with pMD2.G (envelope plasmid), psPAX2 (packaging plasmid) and pWPI-LUC (target plasmid) in 0.1/0.9/1 ratios. Transduced cells expressing eGFP were selected 72 hours after infection by cell sorting on a S3 cell sorter (Bio-Rad).
NOD scid gamma (NSG) mice were injected at 6 weeks of age in the tail vein with 150µl PBS containing 5*10 6 luciferase-labeled LOUCY cells. At regular time points, the bioluminescence was measured using the IVIS Lumina II imaging system (PerkinElmer). At 6 weeks the cells were engrafted and the mice were randomly divided into two groups (in both groups the same amount of males and females) and the treatment was started (day 0). Mice were treated with 100mg ABT-199/kg body weight or with vehicle via oral gavage for four consecutive days. ABT-199 was formulated in 60% phosal 50 propylene glycol, 30% polyethylene glycol 400 and 10%
ethanol. At day 0, day 2 and day 4 the bioluminescene was measured. Before imaging, the mice were injected intraperitoneally with 200µl of a 15mg/ml firefly Dluciferin potassium salt solution and anaesthetized by inhalation of 5% isoflurane.
The mice were imaged ten minutes after luciferin injection. 
Statistical analysis
GraphPad Prism 5.04 (La Jolla, California, USA) was used for statistical analyses.
Results
BCL-2 expression in genetic subtypes of human T-ALL and normal T-cells
To evaluate BCL-2 as a potential therapeutic target in human T-ALL, we analyzed BCL-2 expression levels in T-ALL patients and sorted subsets of normal human thymocytes. Here, we performed microarray gene expression profiling on a panel of 64 primary T-ALL samples and used these gene expression signatures to define different molecular-genetic subtypes of human T-ALL as previously described 6 .
Notably, this analysis revealed that high expression of anti-apoptotic BCL-2 is a 1 0
hallmark of immature subtypes of T-ALL ( Figure 1A ). Moreover, BCL-2 levels were variable in TLX1, TLX3 and HOXA driven T-ALLs and predominantly low in TAL1 rearranged T-cell leukemias ( Figure 1A ). Importantly, these findings were validated and confirmed in an independent cohort of 117 genetically well-characterized human T-ALL samples for which gene expression signatures are publically available 5 ( Figure   1B ). In this validation series, the average BCL-2 expression in the HOXA subgroup was similar to the one in the immature T-ALL subgroup.
As normal T-cell development serves as the conceptual framework for the understanding of T-ALL biology 23 , we hypothesized that high BCL-2 expression in 
Mouse model of immature T-ALL responds to ABT-199
To further study the association between ABT-199 sensitivity and tumor immune phenotype in T-ALL, we used the Lck-Lmo2 transgenic mouse model. Interestingly, we identified a 100-fold difference in value between the immature (#39365; IC 50 = 2.2nM, Figure 4A ) and mature murine T-cell tumor (#39354;
Overexpression of the
IC 50 = 214nM, Figure 4A ) and this differential ABT-199 response was associated with enhanced levels of BCL-2 in the immature murine T-cell tumor ( Figure 4B ).
ABT-199 response in primary T-ALL samples
To define ABT-199 sensitivity in primary patient material, we subsequently selected a panel of 17 pediatric primary T-ALL samples that represent major immunophenotypic maturation stages and molecular genetic subtypes of T-ALL ( Figure Interestingly, the putative relation between tumor immunophenotype and ABT-199 sensitivity was further strengthened by a unique T-ALL sample that presented with a mature T-ALL at diagnosis but suffered from an immature/biphenotypic T-ALL at relapse 11 months after initial diagnosis (Supplementary Figure 3) . Notably, the leukemic clone with an immature/biphenotypic immunophenotype that eventually gave rise to the relapse was already detected at day 15 and day 35 after induction therapy. Notably, in vitro analysis of these paired samples obtained at diagnosis and relapse revealed marked differences in ABT-199 sensitivity. The immature leukemic cells at relapse were highly sensitive to ABT-199 treatment (IC 50 =7.32nM), whereas the mature leukemic cell population at diagnosis barely responded to (IC 50 >800nM, Figure 5B ). Interestingly, the marked difference in ABT-199 sensitivity was accompanied by a notable difference in BCL-2 expression between the diagnostic and relapse sample ( Figure 5C ). Welch's correction) as compared to the vehicle-treated mice ( Figure 5D ).
Combination of ABT-199 and chemotherapeutics
To evaluate potential synergism between ABT-199 and conventional chemotherapeutic agents, T-ALL cell lines were treated with combinations of ABT-199 and doxorubicin, L-asparaginase (Erwinase) or dexamethasone (Aacidexam).
LOUCY and ALL-SIL displayed higher synergism with doxorubicin and Lasparaginase as compared to the ABT-199-insensitive JURKAT cell line (Figure 6A -B;
Supplementary Table 3 ). In addition, the combination of ABT-199 with dexamethasone was strongly synergistic in LOUCY cells ( Figure 6C ; Supplementary 
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